|
Adenocarcinoma
|
0.020 |
GeneticVariation
|
group |
LHGDN |
Spatio-temporal dynamic analysis of bid activation and apoptosis induced by alkaline condition in human lung adenocarcinoma cell.
|
17762183 |
2007 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Effect of Helicobacter pylori infection on expression of Bcl-2 family members in gastric adenocarcinoma.
|
14716828 |
2004 |
|
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We found that the extrinsic apoptotic pathway and the BH3 interacting-domain death agonist (BID) are activated in adenomas from NSAID-treated patients.
|
25368155 |
2014 |
|
Adenomatous Polyposis Coli
|
0.010 |
Biomarker
|
disease |
BEFREE |
We further demonstrate that NSAIDs induce death receptor signaling in both cancer and normal cells, but only activate BID in cells with APC deficiency and ensuing c-Myc activation.
|
25368155 |
2014 |
|
Agnosia for Pain
|
0.010 |
Biomarker
|
disease |
BEFREE |
During week 2, the placebo group exhibited a blunted analgesic response to oxycodone for pain threshold and subjective pain ratings, whereas the 40mg BID ibudilast group exhibited greater analgesia as measured by subjective pain ratings (p≤0.05).
|
28688296 |
2017 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study provides Class III evidence that huperzine A 200 μg BID has no demonstrable cognitive effect in patients with mild to moderate AD.
|
21502597 |
2011 |
|
Anxiety symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We found significant correlations with sleep disorders (r = 0.41, p = ≤ 0.001), BID (r = 0.35, p = 0.04), facial image dissatisfaction (r = 0.35, p = 0.04), mouth disability (r = 0.51, p = 0.005), depressive (r = 0.6, p = ≤ 0.001), and anxiety symptoms (r = 0.48, p = ≤ 0.001), fatigue (r = - 0.45 p = 0.005), SF-36 PCS (r = - 0.51, p = ≤ 0.001) and MCS (r = - 0.65, p = ≤ 0.001).
|
30498976 |
2019 |
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Outpatient children (6 to 20 months old) with recurrent wheezing and risk factors for asthma were randomized to receive a 6-month treatment with metered-dose inhaler (MDI) of Fluticasone Propionate 125 mcg BID through an NVS or through a VHC.
|
30250631 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
The effects of cisplatin include activation of caspases, proteolysis of enzyme poly ADP ribose polymerase (PARP), control of apoptosis modulators B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and BH3-interacting domain death agonist (Bid), and cell cycle arrest in G2/M phase.
|
30845773 |
2019 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Combination treatment reduced the expression of B-cell lymphoma 2 (BCL2), BH3 interacting domain death agonist (BID), and BCL-x/L.
|
30343279 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Here, we report that elevated oxygen (hyperoxia) triggers a marked increase in active caspase-2 expression, resulting in an initiation of the intrinsic apoptotic pathway with upregulation of key proteins, namely, cytochrome c, apoptosis protease-activating factor-1, and the caspase-independent protein apoptosis-inducing factor, whereas BH3-interacting domain death agonist and the anti-apoptotic protein B-cell lymphoma-2 are downregulated.
|
22237207 |
2012 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Importantly, pBD129 elevated the expression level of Bcl-2-associated death promoter (Bcl-2), but down-regulated the expression levels of apoptosis-related genes such as the B-cell lymphoma-2-associated X protein (Bax), BH3-interacting domain death agonist (Bid), cysteinyl aspartate-specific proteinase-3 (Caspase-3), and caspase-9 in the intestinal mucosa (<i>P</i> < 0.05).
|
31636641 |
2019 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
These observations were found to correlate with increases in truncated BH3 interacting‑domain death agonist and B‑cell lymphoma 2 (Bcl‑2) interacting mediator of cell death, but not Bcl‑2 homologous antagonist killer, Bcl‑2‑associated X protein, Bcl‑2, B‑cell lymphoma‑extra large and induced myeloid leukemia cell differentiation protein levels.
|
24270523 |
2014 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, the pro‑apoptotic factors Bcl‑2 X‑associated protein and BH3 interacting domain death agonist were uregulated, while the anti‑apoptotic factors B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2‑extra large were downregulated.
|
29363721 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The results showed that poly (I:C) transfection markedly induced HeLa apoptosis, increased the protein levels of pro‑apoptotic B cell lymphoma‑2 (Bcl‑2)‑associated X protein (Bax) and BH3 interacting‑domain death agonist (Bid), and suppressed the protein expression levels of anti‑apoptotic Bcl‑2 and Survivin.
|
26848042 |
2016 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, our data revealed that Z-IETD-FMK also blocked increase of truncated BH3 interacting domain death agonist (tBID)/BID, decrease of the B-cell lymphoma 2 (Bcl-2)/Bcl-2 associate X protein (Bax) ratio and mitochondrial membrane potential (MMP), release of cytochrome c, as well as cleavage of caspase-9/3 and poly (ADP-ribose) polymerase (PARP) induced by Cd.
|
29891925 |
2018 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Fas ligand (FASL/CD95L) has been shown to induce neutrophil apoptosis, which is accelerated by the processing of the BH3-only protein BH3 interacting domain death agonist (BID) to trigger mitochondrial apoptotic events, and been attributed a regulatory role during viral and bacterial infections.
|
29495595 |
2018 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Decreases in BH3 interacting domain death agonist (BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the OFC.
|
22545112 |
2012 |
|
Bipolar Disorder
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Decreases in BH3 interacting domain death agonist (BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the OFC.
|
22545112 |
2012 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Bone Cysts, Aneurysmal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with HER2-negative ABC that recurred after anthracycline and taxane therapy were randomized (1:1) to sunitinib 37.5 mg/day or capecitabine 1,250 mg/m(2) (1,000 mg/m(2) in patients >65 years) BID on days 1-14 q3w.
|
20339913 |
2010 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
BID(+) and BID(-) breast cancer MCF-7 cells could be considered to be a useful model for the study of the molecular interdependences between apoptosis and autophagy and the role of both processes in cancer therapy.
|
16874058 |
2007 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Fifty-five patients with clinical stage IIA-IIIC breast cancer received 12 weekly doses of paclitaxel (80 mg/m(2)) plus vorinostat (200-300 mg PO BID) on days 1-3 of each paclitaxel dose plus trastuzumab (for Her2/neu positive disease only), followed by doxorubicin/cyclophosphamide (60/600 mg/m(2) every 2 weeks plus pegfilgrastim).
|
24903226 |
2014 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Seviteronel demonstrates linear PK over the dose range of 50-750 mg given either BID or QD in men with advanced CRPC or men and women with breast cancer.
|
31367790 |
2019 |
|
Breast Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have suggested that minor alleles for ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 may influence breast cancer risk, but the evidence is inconclusive due to their small sample size.
|
19423537 |
2009 |